This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Compared to Estimates, Goosehead (GSHD) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Goosehead (GSHD) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Goosehead Insurance (GSHD) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Goosehead (GSHD) delivered earnings and revenue surprises of 325% and 4.24%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
What Makes Goosehead Insurance (GSHD) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Goosehead Insurance (GSHD) have what it takes to be a top stock pick for momentum investors? Let's find out.
CNO Financial (CNO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
CNO (CNO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Goosehead Insurance (GSHD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Goosehead (GSHD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AON Approves 10% Dividend Hike, Boosts Shareholder Value
by Zacks Equity Research
Aon's (AON) recent dividend hike reinforces its solid financial position and intensified focus to enhance shareholders' value.
Are Finance Stocks Lagging Goosehead Insurance (GSHD) This Year?
by Zacks Equity Research
Here is how Goosehead Insurance (GSHD) and Everest Re (RE) have performed compared to their sector so far this year.
MetLife (MET) Collaborates With Savi to Aid Students With Debts
by Zacks Equity Research
MetLife's (MET) Upwise partners with Savi to help students better understand the loan payment process and loan forgiveness eligibility criteria.
Reasons to Hold American International (AIG) Stock for Now
by Zacks Equity Research
Strong General Insurance business, improving premiums and cost-cutting efforts poise American International (AIG) well for growth.
Aflac (AFL) Adds Beneficiary Services to Product Portfolio
by Zacks Equity Research
Aflac (AFL) takes the help of Iris to integrate the Beneficiary Companion service within its life, absence and disability product offerings to ease survivors in settling final affairs post the death of a loved one.
Here's Why You Should Retain MetLife (MET) in Your Portfolio
by Zacks Equity Research
MetLife's (MET) growing partnerships, strong U.S. and Latin America segments, and cost-cutting efforts are aiding its margins.
Oscar Health, Inc. (OSCR) Stock Jumps 56.3%: Will It Continue to Soar?
by Zacks Equity Research
Oscar Health, Inc. (OSCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Why Investors Should Invest in CNO Financial (CNO) Stock Now
by Zacks Equity Research
Strong direct-to-consumer life sales, improving annuity collected premiums and increased Medicare enrolment poise CNO Financial (CNO) well for growth.
Bears are Losing Control Over Goosehead (GSHD), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Goosehead (GSHD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
MetLife (MET) Forms $4B Agriculture Mortgage Loans in 2022
by Zacks Equity Research
MetLife's (MET) asset management arm, MetLife Investment Management, supports agricultural producers by initiating $4 billion of agricultural mortgage loans across 400 notes in 2022.
MetLife (MET) Originates $15.1 billion in Private Placement Debt
by Zacks Equity Research
Issuers turning to private debt will increase private placement assets under MetLife's (MET) asset management arm, boosting management fees.
MetLife's (MET) Asset Management Unit Acquires Raven Capital
by Zacks Equity Research
MetLife's (MET) asset management arm, MetLife Investment Management, acquires Raven Capital with $2.1 billion in assets under management, aiming to expand its offerings in private credit.
Zacks.com featured highlights UWM Holdings, Perion Network, Lantheus Holdings and Goosehead Insurance
by Zacks Equity Research
UWM Holdings, Perion Network, Lantheus Holdings and Goosehead Insurance have been highlighted in this Screen of The Week article.
Add These 4 Top-Ranked Liquid Stocks For Healthy Gains
by Vaishali Doshi
Here are four top-ranked liquid stocks, Goosehead Insurance (GSHD), Lantheus Holdings (LNTH), Perion (PERI) and UWM Holdings (UWMC), which investors can add to their portfolio for strong gains.
Can Goosehead (GSHD) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Goosehead (GSHD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
New Strong Buy Stocks for February 28th
by Zacks Equity Research
GIB, GSHD, IPG, FTAI and BABA have been added to the Zacks Rank #1 (Strong Buy) List on February 28, 2023.
Goosehead Insurance (GSHD) Misses Q4 Earnings Estimates
by Zacks Equity Research
Goosehead (GSHD) delivered earnings and revenue surprises of -8.33% and 10.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Goosehead Insurance (GSHD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Goosehead (GSHD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EverQuote (EVER) Soars 7.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
EverQuote (EVER) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Oscar Health, Inc. (OSCR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Oscar Health, Inc. (OSCR) delivered earnings and revenue surprises of -3.96% and 10.73%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?